Gene · 7277
TUBA4A: tubulin alpha 4a
12 sourcesgene-search-2026-11-11-0.2.0
Cite this record
ConductScience Library. TUBA4A: tubulin alpha 4a. Genes, record 7277. Release gene-search-2026-11-11-0.2.0, 11 Nov 2026. https://conductscience.org/library/genes/7277
On this page
Gene
Proteins1
Reviewed human proteins whose Swiss-Prot entry states the gene.
| UniProt entry | Protein | Length | Structures | Gene stated in |
|---|---|---|---|---|
| P68366 | Tubulin alpha-4A chain | 448 | 0 | Ensembl, GeneID, HGNC |
Source UniProt
Patents61
Patents whose sequence listing contains this protein's exact sequence. A patent can list a sequence without claiming it.
| Publication | Published | SEQ ID NO | Protein | Source |
|---|---|---|---|---|
| EP 4641202 A2 | 2025-10-29 | 4438 | P68366 | Espacenet |
| JP 2025138725 A | 2025-09-25 | 1886 | P68366 | Espacenet |
| KR 1020250017231 A | 2025-02-04 | 4438 | P68366 | Espacenet |
| JP 2023145599 A | 2023-10-11 | 1886 | P68366 | Espacenet |
| JP 2023516705 A | 2023-04-20 | 103 | P68366 | Espacenet |
| US 11446398 B2 | 2022-09-20 | 93561 | P68366 | Espacenet |
| US 11357824 B2 | 2022-06-14 | 970 | P68366 | Espacenet |
| JP 2022524081 A | 2022-04-27 | 196532 | P68366 | Espacenet |
| JP 2022023036 A | 2022-02-07 | 14498 | P68366 | Espacenet |
| WO 2021175788 A1 | 2021-09-10 | 103 | P68366 | Espacenet |
1 to 10 of 61
See all 61 patentsDrugs90
Drugs a ChEMBL mechanism record says act on the gene's protein, through Open Targets.
| Drug | ChEMBL ID | Mechanism | Action | Source |
|---|---|---|---|---|
| AGS-16C3F | CHEMBL4594455 | Tubulin disrupting agent | DISRUPTING AGENT | ChEMBL |
| ANETUMAB RAVTANSINE | CHEMBL2109629 | Tubulin inhibitor | INHIBITOR | ChEMBL |
| ANG1005 | CHEMBL1089636 | Tubulin inhibitor | INHIBITOR | ChEMBL |
| ANVATABART OPADOTIN | CHEMBL4297892 | Tubulin inhibitor | INHIBITOR | ChEMBL |
| APRUTUMAB IXADOTIN | CHEMBL4650293 | Tubulin inhibitor | INHIBITOR | ChEMBL |
| ASG-5ME | CHEMBL2109574 | Tubulin inhibitor | INHIBITOR | ChEMBL |
| AVE-9633 | CHEMBL2109266 | Tubulin inhibitor | INHIBITOR | ChEMBL |
| AZINTUXIZUMAB VEDOTIN | CHEMBL4297859 | Tubulin inhibitor | INHIBITOR | ChEMBL |
| BELANTAMAB MAFODOTIN | CHEMBL4298209 | Tubulin inhibitor | INHIBITOR | ChEMBL |
| BIIB-015 | CHEMBL2109575 | Tubulin inhibitor | INHIBITOR | ChEMBL |
1 to 10 of 90
See all 90 drugsTrials8,728
Trials of those drugs. A trial joins the gene only through a drug that acts on it.
| Trial | Drug | Phase | Results first posted | Source |
|---|---|---|---|---|
| NCT07604766 | PACLITAXEL | PHASE3 | ClinicalTrials.gov | |
| NCT07602907 | PACLITAXEL | PHASE2 | ClinicalTrials.gov | |
| NCT07601737 | PACLITAXEL | PHASE2 | ClinicalTrials.gov | |
| NCT07601178 | PACLITAXEL | PHASE2 | ClinicalTrials.gov | |
| NCT07599163 | PACLITAXEL | ClinicalTrials.gov | ||
| NCT07595770 | PACLITAXEL | PHASE2 | ClinicalTrials.gov | |
| NCT07594548 | PACLITAXEL | PHASE1 | ClinicalTrials.gov | |
| NCT07591467 | DOCETAXEL | PHASE3 | ClinicalTrials.gov | |
| NCT07589972 | VINORELBINE | ClinicalTrials.gov | ||
| NCT07588698 | VINCRISTINE SULFATE | PHASE2 | ClinicalTrials.gov |
1 to 10 of 8,728
See all 8,728 trialsNIH grants1,181
NIH grants whose papers are about the gene, through NIH's grant-paper links.
| Grant | Title | TUBA4A papers | Newest fiscal year |
|---|---|---|---|
| P30CA008748 | Cancer Center Support Grant | 9 | 2025 |
| P30ES017885 | Michigan Center on Lifestage Environmental Exposures and Disease (M-LEEaD) | 4 | 2025 |
| R01GM058921 | Histone mRNA Regulation in Development | 4 | 2025 |
| P30AI027763 | UCSF-Bay Area Center for AIDS Research | 3 | 2025 |
| P50HD105351 | Boston Children's Hospital/HMS Intellectual and Developmental Disabilities Research Center | 3 | 2025 |
| R01AG011085 | Ubiquitin‐mediated proteolysis and cell cycle control | 3 | 2025 |
| R01NS120926 | Creating a foundation for personalized age- and sex-based immune-targeted therapies from an ALS longitudinal cohort by identifying peripheral and central immune signatures | 3 | 2025 |
| R35GM118093 | Structural and functional studies of mRNA processing, stability and quality control | 3 | 2025 |
| R35GM133552 | Coordination of chaperone interactions that dictate protein folding and trafficking | 3 | 2025 |
| U01HG011755 | Broad Institute Mendelian Genomic Research Center | 3 | 2025 |
1 to 10 of 1,181Source NIH's project files
See all 1,181 nih grantsPapers2,174
Newest first. Swiss-Prot's references are curated; PubTator's text mining finds papers that name the gene, not always ones about it.
| Title | Journal | Year | PMID | Found by | Source |
|---|---|---|---|---|---|
| TUBA4A Pathogenic Variant Manifesting With Adulthood-Onset Genetic Myasthenic Syndrome, Myopathy, and Infertility. | Eur J Neurol | 2026 | 42725680 | PubTator, text mining | PubMed |
| Proteomic and metabolomic analysis of human follicular fluid from follicles with different diameters. | Front Cell Dev Biol | 2026 | 42597911 | PubTator, text mining | PubMed |
| A diagnostic signature derived from NK cell related genes in prostate cancer: insights from integrated scRNA-seq and bulk RNA-seq analyses with functional validation of KIT. | Front Immunol | 2026 | 42317356 | PubTator, text mining | PubMed |
| Multi-omics profiling characterizes the primary cilium-related molecular regulatory landscape in systemic lupus erythematosus. | Analyst | 2026 | 42312723 | PubTator, text mining | PubMed |
| Deciphering the role of tubulin's C-terminal tail in kinesin binding using computational and clustering approaches. | Sci Rep | 2026 | 42168523 | PubTator, text mining | PubMed |
| Deciphering cis-regulatory elements using REgulamentary. | Bioinform Adv | 2026 | 41943802 | PubTator, text mining | PubMed |
| Human-Robot Interaction Strategy of Service Robot with Insufficient Capability in Self-Service Shop. | Biomimetics (Basel) | 2026 | 41892136 | PubTator, text mining | PubMed |
| Imaging improvements reveal guttae development and posterior fibrillar layer formation in fuchs endothelial corneal dystrophy. | Sci Rep | 2026 | 41888247 | PubTator, text mining | PubMed |
| Microtubules guide Aurora B substrate geometries for accurate chromosome segregation. | Sci Adv | 2026 | 41880487 | PubTator, text mining | PubMed |
| Construction and Validation of an N7-Methylguanosine-Related Prognostic Model for Acute Myeloid Leukemia. | Blood Lymphat Cancer | 2026 | 41847631 | PubTator, text mining | PubMed |
1 to 10 of 2,174
See all 2,174 papersSources 12
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ChEMBL, through Open TargetsCC BY-SA 3.0
- ClinicalTrials.govNo license stated
- EMBL-EBI's patent proteinsNo added restrictions. Attribution expected
- GenBank's patent filesNo restrictions from NCBI. Submitters may hold rights
- HGNCCC0
- NCBI GenePublic domain (US government)
- NIH's project files and grant-paper linksPublic domain
- Open TargetsCC0 1.0
- PubMedNLM's terms
- PubTator 3Public domain
- UniProtCC BY 4.0
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ChEMBL, through Open TargetsCC BY-SA 3.0, for the parts from ChEMBL. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- ClinicalTrials.govnone stated
- EMBL-EBI's patent proteinsEMBL-EBI's patent protein files from the EPO, JPO, KIPO and USPTO. EMBL-EBI: "EMBL-EBI itself places no additional restrictions on the use or redistribution of the data available via its Data Resources and Tools other than those provided by the original data owners" and "EMBL-EBI expects attribution (e.g. in publications, services or products) for the use of any of its Data Resources and Tools." Read on 11 Nov 2026 at https://www.ebi.ac.uk/about/terms-of-use
- GenBank's patent filesGenBank's patent files. NCBI: "NCBI places no restrictions on the use or distribution of the GenBank data. However, some submitters may claim patent, copyright, or other intellectual property rights in all or a portion of the data they have submitted." Read on 11 Nov 2026 at https://www.ncbi.nlm.nih.gov/genbank/about/
- HGNCCC0: https://www.genenames.org/about/license/
- NCBI GeneNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
- NIH's project files and grant-paper linksPublic domain (NIH RePORTER)
- Open TargetsCC0 1.0. Open Targets asks that users cite its latest paper: Buniello et al. 2025, Open Targets Platform: facilitating therapeutic hypotheses building in drug discovery, Nucleic Acids Research 53(D1):D1467, PMID 39657122. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- PubMedNLM's terms
- PubTator 3Public domain
- UniProtCC BY 4.0. UniProt's licence file: "All databases and documents in the UniProt FTP directory may be copied and redistributed freely, without advance permission, provided that this copyright statement is reproduced with each copy." UniProt asks that users cite its latest paper: The UniProt Consortium, UniProt: the Universal Protein Knowledgebase in 2025, Nucleic Acids Research 53:D609-D617, https://doi.org/10.1093/nar/gkae1010. Read on 9 Nov 2026 at https://www.uniprot.org/help/license
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this gene from software.
The record and each of its lists are JSON, twenty rows a page. No key.
GET https://conductscience.org/api/genes/v1/7277
GET https://conductscience.org/api/genes/v1/7277/patents?page=2